Upper urinary tract urothelial carcinomas (UTUC) account for 5-10% of all transitional cells neoplasms. Kidney-sparing treatment should be considered for low grade (LG) UTUC and for imperative conditions. Percutaneous approach may have a role in LG tumors not manageable endoscopically. Tumor seeding along nephrostomy track is a rare report. We describe the case of a 73-year-old male, with a history of high-grade UC of the left renal pelvis. A CT scan showed the thickening of left renal pelvic wall, and percutaneous biopsy was performed. The patient underwent laparoscopic left nephroureterectomy. Seven months later, he was admitted for left flank pain due to a mass along the percutaneous track site. Mass en-bloc resection was performed, and histopathology finding demonstrated undifferentiated carcinoma, compatible with UTUC metastasis. The percutaneous approach should be considered to be the possible cause of tumor seeding. Multimodal therapy seems mandatory, as highlighted in our outcomes, with 5 years of recurrence free survival.

Keywords:
Upper tract urinary tumors, Percutaneous approach, Multimodal therapy, Cancer seeding, Nephrostomy tract site
1.
Rouprêt M, Babjuk M, Compérat E, et al: European association of urology guidelines on upper urinary tract urothelial cell carcinoma: 2015 update. Eur Urol 2015;68:868-879.
2.
Rouprêt M, Traxer O, Tligui M, et al: Upper urinary tract transitional cell carcinoma: recurrence rate after percutaneous endoscopic resection. Eur Urol 2007;51:709-713; discussion 714.
3.
Huang A, Low RK, deVere White R: Nephrostomy tract tumor seeding following percutaneous manipulation of a ureteral carcinoma. J Urol 1995;153(3 pt 2):1041-1042.
4.
Sorokin I, Welliver RC Jr, Elkadi O, Nazeer T, Kaufman RP Jr: Tumor seeding of percutaneous nephrostomy tract from urothelial carcinoma of the kidney. Case Rep Urol 2013;2013:819470.
5.
Sharma NK, Nicol A, Powell CS: Track infiltration following percutaneous resection of renal pelvic transitional cell carcinoma. Br J Urol 1994;73:597-598.
6.
Treuthardt C, Danuser H, Studer UE: Tumor seeding following percutaneous antegrade treatment of transitional cell carcinoma in the renal pelvis. Eur Urol 2004;46:442-443.
7.
Sengupta S, Harewood L: Transitional cell carcinoma growing along an indwelling nephrostomy tube track. Br J Urol 1998;82:591.
8.
Shin ES, Darcy MD, Mutch D: Metastatic seeding of a percutaneous nephrostomy tract causing cervical carcinoma. AJR Am J Roentgenol 2002;178:933-934.
9.
Corvino C, Meliani E, Masieri L, Lapini A, Serni S, Carini M: Squamous cell carcinoma of the renal pelvis: nephrostomy tract tumour seeding. BJU Int 2003;92(suppl 3):e15.
10.
Shepherd SF, Patel A, Bidmead AM, Kellett MJ, Woodhouse CR, Dearnaley DP: Nephrostomy track brachytherapy following percutaneous resection of transitional cell carcinoma of the renal pelvis. Clin Oncol (R Coll Radiol) 1995;7:385-387.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.